// App-Quantinova.ai

55 : CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, in Combination with Ruxolitinib, in JAK-Inhibitor-Naïve Myelofibrosis Patients: Update of MANIFEST Phase 2 Study

Researchers

Presenter

  • John Mascarenhas

Principal Investigators

  • Andrea Patriarca

  • Timothy Devos

  • Francesca Palandri

  • Raajit K. Rampal

  • Adam J. Mead

  • Marina Kremyanskaya

  • Tim C.P Somervaille

  • Marielle Wondergem

  • Ronald Hoffman

  • Katarina Luptakova

  • Jing Wang

  • Jessica Christo

  • Jennifer A Mertz

  • Gozde Colak

  • James Shao

  • Suresh Bobba

  • Patrick Trojer

  • Adrian Senderowicz

  • Srdan Verstovsek

  • Vikas Gupta

Medical Centers

  • Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai / The Tisch Cancer Institute, New York, NY

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Azienda Ospedaliero Universitaria Maggiore della Carità di Novara SCDU Ematologia, Novara, Italy

  • Department of Hematology and Department of Microbiology and Immunology, University Hospitals Leuven and Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium

  • Institute of Hematology “L. and A. Seràgnoli”, Sant’Orsola-Malpighi University Hospital,Bologna,Italy

  • Leukemia Service, Department of Medicine, Clinical Director, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • The Christie Hospital, Cancer Research UK Manchester Institute, Manchester, United Kingdom

  • Department of Hematology, Academisch Ziekenhuis Vrije Universiteit,Amsterdam,Netherlands

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Constellation Pharmaceuticals, Inc., Cambridge, MA

  • Constellation Pharmaceuticals, CAMBRIDGE, MA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

Locations

  • United States

  • United Kingdom

  • Italy

  • Belgium

  • Netherlands

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Myelofibrosis

  • Anemia

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Nucleoside diphosphate kinase A

  • Calreticulin

Drug/Treatment

  • Ruxolitinib phosphate

  • Fedratinib

  • CPI-0610

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved